Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News SCYNEXIS Inc SCYX

Healthcare

SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It develops antifungal platform fungerps, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a range of human fungal pathogens,... see more

Add To Watchlist

Recent & Breaking News (NDAQ:SCYX)

The Daily Biotech Pulse: Novavax Reports Positive Influenza Vaccine Trial Data, Flexion Warns Of Revenue Shortfall, Retrophin's New CEO

Benzinga.com January 4, 2019

SCYNEXIS Provides Year-end Update and Outlines Plans for 2019

PR Newswire January 3, 2019

Report: Developing Opportunities within ReWalk Robotics, ImmuCell, SCYNEXIS, Fuel Tech, Garrison Capital, and AMREP — Future Expectations, Projections Moving into 2018

GlobeNewswire November 23, 2018

SCYNEXIS, Inc. to Present at Upcoming Investor Conferences

PR Newswire November 20, 2018

Technological Advancements Show Growth in the Hospital Acquired Infection Control Market

PR Newswire November 16, 2018

SCYNEXIS Reports Third Quarter 2018 Financial Results and Provides Company Update

PR Newswire November 13, 2018

Data Projects the Global Medical Device Industry is Set to Grow

PR Newswire October 26, 2018

SCYNEXIS Announces FDA Agreement with Company-Proposed Phase 3 Vulvovaginal Candidiasis Program for Oral Ibrexafungerp

PR Newswire October 23, 2018

SCYNEXIS, Inc. Announces First Patient Dosed in Phase 3 Open-label Study Evaluating Oral Ibrexafungerp in Candida auris Infections (CARES)

PR Newswire October 15, 2018

Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2018

PR Newswire October 3, 2018

SCYNEXIS Supports AMR Challenge and Fungal Disease Awareness Week

PR Newswire October 1, 2018

SCYNEXIS to Present an Overview of the Company's Pipeline at IDWeek 2018

PR Newswire September 26, 2018

SCYNEXIS, Inc. to Present at Upcoming Investor Conferences

PR Newswire September 25, 2018

SCYNEXIS, Inc. Presents Ibrexafungerp Data at the 2018 ESCMID/ASM Conference on Drug Development

PR Newswire September 4, 2018

SCYNEXIS, Inc. to Participate in Upcoming Investor Conferences

PR Newswire August 29, 2018

SCYNEXIS Reports Second Quarter 2018 Financial Results and Provides Company Update

PR Newswire August 9, 2018

SCYNEXIS Reports Positive Results from Phase 2b Dose-Finding Study of Oral SCY-078 in Vulvovaginal Candidiasis

PR Newswire July 10, 2018

SCYNEXIS Announces the Presentation of SCY-078 Data at the Teratology Society 58th Annual Meeting

PR Newswire June 27, 2018

SCYNEXIS to Present SCY-078 Data at Three Scientific Meetings in June/July 2018

PR Newswire June 14, 2018

SCYNEXIS Presents SCY-078 Data at ASM Microbe 2018

PR Newswire June 11, 2018